文献速递心外重症与机械循环支持

VA-ECMO治疗难治性心源性休克的生存率与健康相关生活质量

Extracorporeal membrane oxygenation for refractory cardiogenic shock: patient survival and health-related quality of life.
PubMed 文献 · Eur J Cardiothorac Surg · 2019-01-01

单中心2007至2016年133例难治性心源性休克患者接受VA ECMO的回顾性研究。出院生存率63.9%,1年生存率60.9%;HCO3较低与红细胞输注需求增加独立关联院内死亡升高。长期HRQoL与一般人群相当,仅躯体健康受限。

要点

  • VA ECMO后出院生存率63.9%、1年生存率60.9%,长期HRQoL总体良好。
  • 植入时HCO3每降低1 mmol/l,院内死亡OR 1.2;ICU每日红细胞每增1单位,OR 1.9。
  • ≤60岁存活者中56%重返工作,躯体健康是主要受限领域。

核心结论

  • VA ECMO可为经选择的难治性心源性休克患者提供可接受的长期生存与良好HRQoL。
  • 患者评估与VA ECMO植入时机至关重要,酸中毒越深院内死亡率越高。

研究设计与样本

  • 单中心2007至2016年连续133例接受VA ECMO治疗的患者的回顾性研究。
  • HRQoL采用EuroQuol-5 dimensions-3 level问卷与RAND 36条目简表,于VA ECMO后至少1年评估。

主要发现

  • 66例(49.6%)脱离VA ECMO,16例(12.0%)直接桥接移植,15例(11.3%)桥接心室辅助装置,1例(0.8%)桥接全人工心脏。
  • 出院生存率63.9%,1年生存率60.9%。
  • 院内死亡升高独立关联植入时较低HCO3[OR 1.2/HCO3每降低1 mmol/l(95%CI 1.1-1.3,P<0.001)]。
  • 院内死亡升高独立关联ICU期间红细胞输注需求增加[OR 1.9/每日所需红细胞每单位(95%CI 1.4-2.6,P<0.001)]。
  • EuroQuol-5 dimensions-3 level问卷HRQoL与一般人群相当;36条目简表中情绪健康更好,精力、疼痛与总体健康感知相当,仅躯体健康受限。

临床怎么用

  • 对难治性心源性休克可行VA ECMO,需把握患者评估与植入时机,避免过深酸中毒。
  • 关注ICU期间红细胞输注需求,作为院内死亡风险增高的提示。
  • 存活者长期HRQoL总体良好,康复重点可放在躯体功能。

局限性

  • 为单中心回顾性研究,样本来自2007至2016年连续133例患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Our goal was to study the outcome of patients with cardiogenic shock who were treated with venoarterial extracorporeal membrane oxygenation (VA ECMO), including the subsequent long-term health-related quality of life (HRQoL). METHODS: We conducted a retrospective study of 133 consecutive patients treated in a single centre from 2007 to 2016. The HRQoL was studied using the EuroQuol-5 dimensions-3 level questionnaire and the RAND 36-Item Short Form Health Survey at a minimum of 1 year after VA ECMO. RESULTS: Of all patients, 66 (49.6%) were weaned from VA ECMO and 16 (12.0%) patients were bridged directly to a transplant, 15 (11.3%) to a ventricular assist device and 1 (0.8%) to a total artificial heart. Survival to discharge was 63.9% and to 1 year, 60.9%. A higher in-hospital mortality rate was independently associated with lower HCO3 at VA ECMO implantation [odds ratio (OR) 1.2/decrease of 1 mmol/l in HCO3 (95% confidence interval 1.1-1.3, P < 0.001)] and with increased need of red blood cells transfused during intensive care [OR 1.9/unit of red blood cells needed/day (95% confidence interval 1.4-2.6, P < 0.001)]. HRQoL measured with the EuroQuol-5 dimensions-3 level questionnaire was equal to the HRQoL of the general population. In the 36-Item Short Form questionnaire, patients reported better emotional well-being and equal energy, pain and general health perception compared to the general population. Limitations were experienced only in physical health. In total, 56% of the patients ≤ 60 years had returned to work. CONCLUSIONS: VA ECMO can provide acceptable long-term survival with good HRQoL for selected patients with refractory cardiogenic shock. Timing of patient assessment and of VA ECMO implantation is essential because deeper acidosis is associated with a higher in-hospital mortality rate.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Jäämaa-Holmberg S, Salmela B, Suojaranta R, et al. Extracorporeal membrane oxygenation for refractory cardiogenic shock: patient survival and health-related quality of life. Eur J Cardiothorac Surg. 2019. PMID: 30534984. doi:10.1093/ejcts/ezy374

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。